ES2161538T3 - Utilizacion de un veneno de serpiente para provocar la coagulacion por activacion del factor x en xa. - Google Patents

Utilizacion de un veneno de serpiente para provocar la coagulacion por activacion del factor x en xa.

Info

Publication number
ES2161538T3
ES2161538T3 ES98929499T ES98929499T ES2161538T3 ES 2161538 T3 ES2161538 T3 ES 2161538T3 ES 98929499 T ES98929499 T ES 98929499T ES 98929499 T ES98929499 T ES 98929499T ES 2161538 T3 ES2161538 T3 ES 2161538T3
Authority
ES
Spain
Prior art keywords
apc
activation
factor
snake poison
cause coagulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98929499T
Other languages
English (en)
Inventor
Dreden Patrick Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diagnostica Stago SAS
Original Assignee
Diagnostica Stago SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnostica Stago SAS filed Critical Diagnostica Stago SAS
Application granted granted Critical
Publication of ES2161538T3 publication Critical patent/ES2161538T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LA UTILIZACION DE UN VENENO DE SERPIENTE PARTICULAR, EL VENENO DE CROTALUS VIRIDIS HELLERI, PARA DETERMINAR LA REACTIVIDAD DE LA PROTEINA C ACTIVADA (APC), PARTICULARMENTE PARA DETERMINAR LA ACTIVIDAD FUNCIONAL DE LA PROTEINA C Y PARA DETERMINAR LA RESISTENCIA (APC-R) A APC. LA INVENCION SE REFIERE TAMBIEN A UN PROCEDIMIENTO PARA LA DETERMINACION DE APC-R DE UN PLASMA HUMANO QUE HAY QUE PROBAR, ASI COMO AL KIT DE DOSIFICACION PARA PONER EN PRACTICA ESTE PROCEDIMIENTO.
ES98929499T 1997-06-06 1998-06-05 Utilizacion de un veneno de serpiente para provocar la coagulacion por activacion del factor x en xa. Expired - Lifetime ES2161538T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9707041A FR2764389B1 (fr) 1997-06-06 1997-06-06 Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee

Publications (1)

Publication Number Publication Date
ES2161538T3 true ES2161538T3 (es) 2001-12-01

Family

ID=9507700

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98929499T Expired - Lifetime ES2161538T3 (es) 1997-06-06 1998-06-05 Utilizacion de un veneno de serpiente para provocar la coagulacion por activacion del factor x en xa.

Country Status (6)

Country Link
US (1) US6251619B1 (es)
EP (1) EP0956509B1 (es)
DE (1) DE69801806T2 (es)
ES (1) ES2161538T3 (es)
FR (1) FR2764389B1 (es)
WO (1) WO1998055875A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP159698A0 (en) * 1998-02-02 1998-02-26 Life Therapeutics Limited Improved blood coagulation test
DE102005048693B4 (de) * 2005-10-11 2009-07-09 Assa Abloy Sicherheitstechnik Gmbh Türöffneranordnung sowie Adapterstück zur Verwendung in einer Türöffneranordnung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1659486A1 (ru) * 1989-03-02 1991-06-30 МГУ им.М.В.Ломоносова Способ определени антикоагул нта протеина С в плазме крови животных
US5686567A (en) * 1989-06-16 1997-11-11 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5318899A (en) * 1989-06-16 1994-06-07 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5342830A (en) * 1990-11-16 1994-08-30 Cor Therapeutics, Inc. Antithrombosis agents
HU207585B (en) 1990-12-19 1993-04-28 Zoltan Vincze Laboratory reagent set for measuring blood coagulation time and method for obtaining effective agents
DE69207607T3 (de) * 1991-11-13 2006-07-06 T.A.C. Thrombosis And Coagulation Ab Verfahren zur diagnose von störungen der blutgerinnung
AUPM731394A0 (en) * 1994-08-05 1994-09-01 Life Therapeutics Limited Improved activated protein c resistance test
ES2154703T5 (es) * 1994-11-10 2008-02-01 Dade Behring Marburg Gmbh Procedimiento para la deteccion especifica de un factor de coagulacion v activado con una estabilidad elevada frente a proteina c activada.
US5705395A (en) * 1994-11-14 1998-01-06 The Scripps Research Institute Method for diagnosis of thrombotic disorders

Also Published As

Publication number Publication date
EP0956509B1 (fr) 2001-09-26
US6251619B1 (en) 2001-06-26
DE69801806D1 (de) 2001-10-31
WO1998055875A1 (fr) 1998-12-10
DE69801806T2 (de) 2002-05-29
EP0956509A1 (fr) 1999-11-17
FR2764389A1 (fr) 1998-12-11
FR2764389B1 (fr) 1999-08-06

Similar Documents

Publication Publication Date Title
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
ATE442185T1 (de) Handstück zur gewebebehandlung
MA28153A1 (fr) Acides nucléiques se liant spécifiquement à la ghréline biologiquement active
ATE368853T1 (de) Zell-selektives abgabe system
ES2572454T3 (es) Tratamiento de enfermedades mediadas por los linfocitos T
WO2008071898A3 (fr) Appareil de traitement par emission de flashs lumineux avec dispositif d'anti-eblouissement
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
BRPI0416628A (pt) uso de compostos orgánicos
UA88500C2 (ru) Многослойная повязка, пригодная для сокращения продолжительности процесса заживления ран
UY28945A1 (es) Derivados de pirrolopiridina
PE20050477A1 (es) Terapia de combinacion para la infeccion de hcv
AR048135A1 (es) Uso de gen de amiloide a serico en el diagnostico y tratamiento del glaucoma y en la identificacion de agentes anti-glaucoma.
AR041713A1 (es) Una composicoin farmaceutica de duracion prolongada
AR039629A1 (es) Antagonistas de proteinas mcp
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
ES2161538T3 (es) Utilizacion de un veneno de serpiente para provocar la coagulacion por activacion del factor x en xa.
TW200509863A (en) Irradiation device for medical use
ATE395602T1 (de) Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
ES2162068T3 (es) Peptidos que ligan el factor ix, derivados del factor viii y su utilizacion como inhibidores de la coagulacion de la sangre.
ES2068325T3 (es) Metodo y juego o kit para determinar la actividad funcional de la proteina s en el plasma humano.
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
ATE537823T1 (de) Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin
AR029540A1 (es) COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
NO20083191L (no) Farmasoytisk sammensetning for behandling av hemoragisk sjokk og dens etterfolgende symptomer
ATE337020T1 (de) Fettsaure analoge zur diagnose von kranzarterie erkrankungen

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 956509

Country of ref document: ES